<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097851</url>
  </required_header>
  <id_info>
    <org_study_id>PR88202</org_study_id>
    <nct_id>NCT00097851</nct_id>
  </id_info>
  <brief_title>Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase II Trial of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Biotechnology Corporation</source>
  <brief_summary>
    <textblock>
      PI-88 is a new experimental drug that inhibits tumour growth by reducing the formation of new&#xD;
      blood vessels into tumours. Docetaxel is a standard second-line treatment offered to patients&#xD;
      with non-small-cell lung cancer who haven't responded to first-line therapies (platinum-based&#xD;
      drugs or radiotherapy). Of this group of patients, only 20% remain progression-free 6 months&#xD;
      after starting docetaxel treatment. The PR88202 study has been designed to compare two&#xD;
      different cancer treatments (docetaxel only, and docetaxel plus PI-88) and to work out which&#xD;
      is more effective against the cancer. It is hoped that the combination of PI-88 with&#xD;
      docetaxel will allow patients to extend the time it takes for their disease to progress, and&#xD;
      also to improve their quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PR88202 is an open-label randomized study. In the initial phase of the study, patients will&#xD;
      be randomized to receive weekly docetaxel alone, or PI-88 in combination with weekly&#xD;
      docetaxel. Both groups will receive docetaxel (30 mg/m2), administered by intravenous&#xD;
      infusion on days 1, 8 and 15 of a 28-day cycle. The second group only will receive PI-88 (250&#xD;
      mg/day) in addition to docetaxel; PI-88 will be administered by subcutaneous injection on&#xD;
      days 1-4, 8-11 and 15-18 of each cycle. The primary efficacy endpoint is the non-progression&#xD;
      rate at 6 months. In the extension phase of the study, patients in the combination arm who&#xD;
      have stable disease or an objective response after up to six treatment cycles will remain on&#xD;
      PI-88 alone as maintenance therapy. Patients who initially receive docetaxel alone and who&#xD;
      have disease progression or unacceptable toxicity before the completion of six cycles will be&#xD;
      eligible to receive PI-88 alone as third-line therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PI-88</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically or cytologically confirmed stage IIIb or IV NSCLC that has progressed&#xD;
             during or after first-line treatment&#xD;
&#xD;
          -  measurable disease by spiral CT chest scan, as defined in RECIST criteria&#xD;
&#xD;
          -  performance status 0-1 (ECOG)&#xD;
&#xD;
          -  life expectancy at least 2 months&#xD;
&#xD;
          -  adequate hemopoietic, renal and hepatic function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current symptomatic central nervous system (CNS) involvement&#xD;
&#xD;
          -  prior or co-existent malignancies&#xD;
&#xD;
          -  significant non-malignant disease&#xD;
&#xD;
          -  acute or chronic gastrointestinal (GI) bleeding in last two years&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  abnormal bleeding tendency&#xD;
&#xD;
          -  patients at risk of bleeding due to open wounds or planned surgery&#xD;
&#xD;
          -  clinically significant hemoptysis within the past 4 weeks&#xD;
&#xD;
          -  bilirubin &gt; upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &gt; 2.5 times ULN, or &gt; 1.5 times ULN if alkaline phosphatase &gt; 2.5 times&#xD;
             ULN&#xD;
&#xD;
          -  alkaline phosphatase &gt; 5 times ULN, unless patient has bone metastases&#xD;
&#xD;
          -  myocardial infarction, stroke or congestive heart failure within last 3 months&#xD;
&#xD;
          -  prior treatment with docetaxel&#xD;
&#xD;
          -  concomitant treatment with aspirin (&gt;100 mg/day), NSAIDs (except selective COX-2&#xD;
             inhibitors, warfarin (&gt;1 mg/day), heparin, LMWH, anti-platelet drugs, CYP3A4&#xD;
             inhibitors&#xD;
&#xD;
          -  women who are pregnant or breast-feeding&#xD;
&#xD;
          -  women of child-bearing potential not using adequate contraception&#xD;
&#xD;
          -  history of allergy and/or hypersensitivity to anti-coagulants or thrombolytic agents,&#xD;
             especially heparin&#xD;
&#xD;
          -  history of immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura or&#xD;
             other platelet disease&#xD;
&#xD;
          -  allergy to polysorbate 80 (component of TaxotereÂ®)&#xD;
&#xD;
          -  uncontrolled or serious infection in last 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Pavlakis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal North Shore Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Mitchell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Austin and Repatriation Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sydney Cancer Centre, Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Haematology and Oncology Clinics</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nambour General Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3187</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>November 30, 2004</study_first_submitted>
  <study_first_submitted_qc>November 30, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2004</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>second-line</keyword>
  <keyword>combination</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>anti-angiogenic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

